Pfizer (NYSE:PFE) Hits New 52-Week Low at $25.26

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as $25.26 and last traded at $25.30, with a volume of 19767977 shares. The stock had previously closed at $25.42.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Argus lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. TD Cowen lowered Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $36.88.

Pfizer Price Performance

The firm's fifty day simple moving average is $27.14 and its 200 day simple moving average is $28.74. The firm has a market cap of $143.74 billion, a P/E ratio of 70.51, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. The business's revenue was down 41.3% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in shares of Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company's stock valued at $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its position in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company's stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company's stock valued at $2,985,783,000 after buying an additional 8,473,686 shares during the period. Morgan Stanley boosted its position in shares of Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company's stock valued at $2,817,055,000 after buying an additional 348,628 shares during the period. Finally, Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $2,129,927,000. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.